MedWatch

Bavarian CFO: There is a tendency to forget the good things

Despite getting a bad knock in the third quarter of the year, Bavarian Nordic has weathered the storm more or less as it expected to. The company’s CFO encourages to also focus on the good results.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

GSK får FDA nik til potentiel revolutionerende HIV-behandling

GSK har fået grønt lys fra de amerikanske lægemyndigheder, FDA, til selskabets mest lovende HIV-middel. Tilladelsen kan være indledningen til et paradigmeskifte inden for HIV-behandling, idet behandlingen reducerer antallet af lægemidler, patienterne behøver at tage.

Latest Top picks in English

Related articles